Dose-Finding Study of Ivermectin in the Treatment of COVID-19

Dose-Finding study of Ivermectin treatment on patients infected with Covid-19:A clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200408046987N1

Enrollment

125

Registered

2020-04-27

Start date

2020-05-04

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19

Interventions

Intervention 1: Control group: Standard regimen based on Iran health ministry. Intervention 2: Intervention group: Standard regimen based on Iran health ministry plus low dose Ivermectin(200 mcg/kg ,

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients who test positive for COVID-19 by a commercially available Test Patients = 20 but < 65 years of age with a temperature (oral) of 38°C patients 65 - 80 years of age with a temperature (oral) of 37.8°C Patients with 2 or more of the following symptoms (moderate to severe in intensity) at the time of enrollment: Cough Sore throat Headache Nasal congestion Feeling feverisho Body aches and pains Fatigue (tiredness)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Chest image(CT scan). Timepoint: at hospital clearance. Method of measurement: Patient's profile(CT scan image).;Hospitalization time. Timepoint: end of intervention. Method of measurement: Hospitalization time.;CBC and CRP. Timepoint: Before intervention, 7 days after intervention. Method of measurement: Sampling and lab test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNematollah Gheibi

Qazvin University of Medical Sciences

ngheibi@qums.ac.ir+98 28 3332 8212

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026